knowledge -WSS

knowledge

author：entertainment 2025-09-02 22:23:13 - browse：28

Adobe

The Food and Drug Administration is expected to approve Merck’s drug to treat a rare lung disorder called pulmonary arterial hypertension on Tuesday, making available a novel treatment for a deadly condition that’s long been challenging to treat.

In a large trial published last year, the drug, called sotatercept, exceeded expectations in significantly increasing the distance that patients could walk and cutting the risk that their condition would worsen, that they would die, and that they would need new treatments.

Pulmonary arterial hypertension, or PAH, is estimated to occur in 15 to 50 per million people, mostly in women. It’s characterized by a proliferation of cells in the blood vessels that connect the right side of heart to the lungs, making it harder for blood to pass through and leading the heart to have to work harder to pump blood into the lungs. The disease, which causes difficulty breathing, fatigue and dizziness, has a high mortality rate, with one study finding that one-fifth of patients died at around three years after diagnosis.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Moonlake's readout produced a cash windfall. Risks remain
Next article： Hospitals use virtual reality to design more inclusive rooms for kids

WSS

A controversial new treatment promises to make little people taller

Alnylam reports growth in sales of rare disease treatments

Chris Christie meets with Zelenskyy during Ukraine trip

Astronauts get first look at the spacecraft that will fly them around the moon

Boston man files lawsuit seeking to bankrupt white supremacist group he says assaulted him

Judge schedules Friday hearing on proposed protective order in Jan. 6 case

explore

knowledge

knowledge

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Flint parents haunted by uncertainty, fears of lead poisoning

Moonlake's readout produced a cash windfall. Risks remain

FDA approves Sage Therapeutics’ rapid

State Dept. review finds Biden bears some blame for Afghanistan failures

Listen: Biotech layoffs, eye drug drama, & gene therapy milestones

Moonlake's readout produced a cash windfall. Risks remain

The painfully weak evidence on taking collagen to treat arthritis

After affirmative action ruling, medical educators look to 'holistic review'

Zapping the brain for stroke rehab: Pivotal clinical trial begins

leisure time

Florida officials tell state schools to teach AP Psychology 'in its entirety'

Astronauts get first look at the spacecraft that will fly them around the moon

Study links childhood stress with decline in older age

FDA scientists endorse Pfizer/BioNTech Covid

More regulation could be coming for drug ads

explore

knowledge

hotspot

focus

entertainment